



Agenda: October 14, 2025



**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**
NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, October 14, 2025
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
Join the meeting now Meeting ID: 279 036 560 437 Passcode: Af3wD7uZ Download Teams Join on the web	+1-858-252-2734 (US Toll) Phone Conference ID: 487 770 789#

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of July 2025 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be Reviewed as Single Products:
 - i. Zelsuvmi™ (*Dermatologics: Topical Antiviral Agents*)
 - ii. Vykati™ XR (*Non-PDL*)
 - iii. Tryptyr® (*Ophthalmic: Immunomodulators*)
 - iv. Andembry® (*Non-PDL*)
 - v. Sephience™ (*Non-PDL*)
 - vi. Anzupgo® (*Immunomodulators: Atopic Dermatitis*)
 - vii. Ekterly® (*Non-PDL*)
- V. Therapeutic Classes with Recommended Changes**
 - a. Acne Agents, Oral
 - b. Antiemetics and Antivertigo Agents
 - c. Cytokine and Cell-Adhesion Molecule (CAM) Antagonists
 - d. Immunomodulators, Atopic Dermatitis
 - f. Stimulants and Related Agents
 - g. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
 - h. Antivirals, Oral
 - i. Chronic Obstructive Pulmonary Disease (COPD) Agents



VII. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Acne Agents, Topical • Antibiotics, Topical • Antifungals, Topical • Antiparasitics, Topical • Antipsoriatics, Oral • Antipsoriatics, Topical • Antivirals, Topical • Rosacea Agents, Topical • Steroids, Topical • Anticholinergic/Antispasmodics • Antidiarrheals • Anti-Ulcer Protectants • Bile Salts • GI Motility, Chronic • H. Pylori Treatment • Histamine II Receptor Blockers • Laxatives and Cathartics • Proton Pump Inhibitors • Ulcerative Colitis Agents • Immunomodulators, Asthma • Immunosuppressives, Oral • Multiple Sclerosis Agents • Muscular Dystrophy Agents • Spinal Muscular Atrophy 	<ul style="list-style-type: none"> • Ophthalmics, Antibiotics • Ophthalmics, Antibiotic-Steroid Combinations • Ophthalmics, Antihistamines • Ophthalmics, Anti-Inflammatory Steroids • Ophthalmics, Antivirals • Ophthalmics, Beta Blockers • Ophthalmics, Carbonic Anhydrase Inhibitors • Ophthalmics, Combinations for Glaucoma • Ophthalmics, Glaucoma Agents (Other) • Ophthalmics, Immunomodulators • Ophthalmics, Mast Cell Stabilizers • Ophthalmics, Mydriatic • Ophthalmics, NSAIDs • Ophthalmics, Prostaglandin Agonists • Ophthalmics, Sympathomimetics • Otics, Anesthetics and Anti-Inflammatories • Otic Antibiotics
--	---

VIII. Adjournment

- a. Schedule of Upcoming Meetings
i. **January, 2026, TBD**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.